Posted by novelagent on June 14, 2012, at 7:38:57
In reply to Re: SLS.. An awsome xenobiologic that U DONT KNOW ABOU » novelagent, posted by SLS on June 14, 2012, at 1:28:04
> I bet cariprazine and Abilify display some potential for treating cocaine addiction - much like buprenorphine aids in the treatment of heroin addiction. The key here is partial agonism at the relevant receptors; D2/D3 dopamine receptors for cocaine and µ opioid receptors for heroin.
Abilify increased meth use in one study... beyond that, it's typically weak. The literature typically lists a host of meds that do nothing, and then conclude with positive, cautious results about replacement therapy of a stimulant like dexedrine for cocaine or meth addiction. Abilify has been studied in meth studies a lot, anyhow.
Shire's patent on Vyvanse includes the part about the dose plateauing shortly after reaching the therapeutic range (it plateaus at 200mg, after which, of course, it doesn't bind to lyseine, and the active part isn't metabolized as d-amphetamine past 200mg).
Unfortunately, even therapeutic ranges of amphetamine are prone for people to call "abuse" if the right intention doesn't seem to be in it... it becomes almost a moral thing, with people questioning how pure one's intention is, nevermind the science. I have difficulty calling something "abuse" if it's within the therapeutic range, regardless of whether an addict *thinks* he/she is "abusing it."
An addict's likability for Vyvanse is lower, but if they feel a bit chipper, they're still going to call a therapeutic feeling a "high," and as a result, well, we can't give people something that makes them feel "high," so all this research on substitution therapy with d-amphetamine is mostly an academic exercise-- what doctors are actually practicing it in the real world? Probably not many.